Latest News

💨 Non‑Invasive Glucose Monitoring: The Game‑Changer for Type 2 Diabetes & Beyond? Thrilled to read Mader & Heinemann’s new review (2026) in Journal of Diabetes Science and Technology: “The Potential Role of Noninvasive Glucose Monitoring in the Management of People with Type 2 Diabetes”. Why this matters – not just for adherence, but for overcoming clinical inertia too: ✅ Pain‑free monitoring – no finger pricks, higher adherence. ✅ Cost savings – ditch expensive strips & sensors. ✅ Simple onboarding and accessibility – breathe & know, anytime, anywhere. ✅ Overcomes inertia – effortless entry for prediabetes, biohackers, and even healthy individuals wanting regular metabolic insights. The paper spotlights our breath‑based VOC technology, including the BOYDSense‑GM study with 98.7% in Zone A/B of the Parkes Error Grid! “Noninvasive VOC‑based glucose monitoring holds promise as a user‑friendly and potentially cost‑effective alternative.” The future of metabolic health starts with a breath. Who’s ready? 💨 #BOYDSense #NonInvasiveGlucose #Type2Diabetes #Prediabetes #Biohacking #DiabetesTech #HealthTech https://lnkd.in/eAZ9a2r9

BOYDSense`s first peer-reviewed publication! 🚀 Thrilled to announce that BOYDSense proudly sponsored the BOYDSense-GM Study, now published in the Journal of Diabetes Science and Technology. This prospective clinical trial with 130 adults with type 2 diabetes validates our breath-based VOC analyzer prototype for non-invasive glucose estimation—achieving 98.7% of estimates in clinically acceptable Parkes error grid zones A/B (T1D grid) and 99.7% (T2D grid), with 99%+ valid measurements on the first breath. This is just the beginning! While our first publication, we’ve already completed 4 clinical trials involving over 370 subjects, building a strong foundation for breath analysis in metabolic health monitoring. Non-invasive, user-friendly, and highly reliable—patients loved it, with 95% finding it easy to use and 86% willing to check daily (vs. current SMBG). Ready to revolutionize the metabolic chaos? DM me to book a call and dive deeper into the results, tech, or partnership opportunities! 📞 #MedTech #DiabetesCare #NonInvasiveGlucose #BOYDSense #HealthTech #ClinicalTrials Link to study: https://lnkd.in/eEk2yhKs

We have reached another important milestones: We are now ISO 13485 certified, confirming that our quality management system meets the rigorous international standard for medical devices. This strengthens the foundation for bringing our non-invasive breath analysis technology for chronic diseases to regulated markets and for building trust with partners, clinicians and patients. A big thank you to the BOYDSense team and our partner seleon GmbH for their expertise, dedication and hard work in making this happen. #ISO13485 #MedTech #Quality #MedicalDevices #BOYDSense #Seleon

We are thrilled to share this article about BOYDSense A big thank you to Matt Brady and HealthTechAsia for taking the time to highlight our work on preventative health via the exhaled breath. We truly appreciate the thoughtful coverage and the opportunity to share our story with a wider audience.

🚀 Exciting News! Our CEO, Ben Delhey, was recently featured in an exclusive interview with MedTech Strategist. In the interview, Ben discusses the pioneering work we are doing with our novel breath-based platform for noninvasive glucose and metabolic monitoring — a breakthrough approach set to transform how metabolic health is managed. Discover insights on the technology’s potential impact, our journey in innovation, and the future of consumer health diagnostics. Don’t miss this chance to learn from the leader driving these cutting-edge advances in medtech. Read the full interview here: #MedTechStrategist #BreathAnalysis #DigitalHealth #Innovation #NoninvasiveMonitoring #MetabolicHealth #MedTech

🎥 New YouTube Video: Innovation in Metabolism Tracking & Diabetes Care This year’s Gitex Global tech summit was the perfect platform to share our progress in metabolic health innovation. Thanks to Kieran O'Connor, who recorded a video live at the event, unpacking how our device analyzes real-time metabolism—including diabetes ranges—with validated clinical trial results . The discussion highlights: • Clinical data on what it means for diabetes management • The journey of starting a cutting-edge healthtech company in Germany • The essential support received from the European Innovation Council (EIC) powering our mission https://lnkd.in/eH3pPamN #GitexGlobal #Metabolism #DiabetesCare #ClinicalTrials #HealthTech #StartupGermany #EICsupport